Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer

Table 3

Results of simple and multiple Cox regression models for overall survival. Hazard ratios (HR) with 95% confidence intervals (CI) and values (p) and proportions of explained variation (PEV). Full model PEV = 21.8%.

Variables	Simple; HR (95%, CI)	value	PEV	Multiple; HR (95%, CI)	value	PEV
Alb < 35	1.01 (0.61–1.68)	0.97	0.0	0.92 (0.54–1.58)	0.763	0.0
CRP > 1	1.63 (1.12–2.38)	0.011	1.6	1.47 (0.97–2.24)	0.070	0.3
N1	3.42 (2.01–5.82)	<0.001	12.4	1.93 (0.98–3.77)	0.007	3.1
N2	3.13 (2.21–4.43)	<0.001	12.4	2.37 (1.50–3.74)	<0.001	3.1
Nres	0.90 (0.77–1.05)	0.18	0.3	0.70 (0.59–0.83)	<0.001	3.2
nEAC	1.85 (1.21–2.84)	0.005	4.2	1.03 (0.62–1.72)	0.903	1.2
nESCC	0.82 (0.78–1.42)	0.482	4.2	0.85 (0.47–1.53)	0.589	1.2
One-stage surgery	0.56 (0.33–0.94)	0.027	1.5	0.80 (0.46–1.41)	0.447	0.1
UICC		<0.001	13.5		0.013	3.0
I versus 0	0.59 (0.26–1.30)	0.186		0.77 (0.33–1.82)	0.555
II versus 0	2.03 (1.00–4.13)	0.052		1.94 (0.89–4.21)	0.093
III + IV versus 0	2.90 (1.45–5.84)	0.003		2.58 (1.08–6.14)	0.033

Effect of at least one pos. LK has time-dependent effect ( in simple model, in multiple model). HR and 95% CI given are evaluated at 48 months; p value given refers to whole (time-dependent) effect, including neoadjuvant-treated and untreated cases. N1 and N2 together also in “simple” model, including neoadjuvant-treated and untreated cases. HR for log2-transformed variables quantify the effect of a doubling of the respective variable. Neoadjuvant therapy and tumor biology (EAC and ESCC) exhibit a significant interaction () in the model containing only these two variables but not in the multivariable model (). Thus, the neoadjuvant therapy effect is given separately for nEAC and nESCC.